Ahmad Reza Farmani

Dr. Ahmad Reza Farmani

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Platelets
Verified
Journal Article
Closed access
AFAhmad Reza Farmani
Ahmad Reza Farmani
MNMohammad Hossein Nekoofar
Mohammad Hossein Nekoofar
SBSomayeh Ebrahimi Barough
Somayeh Ebrahimi Barough
MAMahmoud Azami
Mahmoud Azami
NRNima Rezaei
Nima Rezaei
JAJafar Ai
Jafar Ai
Bone tissue engineering (BTE) is a strategy for reconstructing bone lesions, which is rapidly developing in response to higher demands for bone repairing. Recently, this method, along with the emergence of functionally graded, biocompatible and biodegradable materials, has been expanded. Moreover, scaffolds with chemical, physical and external patterns have induced bone regeneration. However, the maintenance of healthy bone and its regeneration in the human body needs a series of complex and accurate processes. Hence, many studies have been accompanied for reconstructing bone by using blood-derived biomaterials, especially platelet-rich fabricates. The most important reason for using platelet-rich formulations in bone regeneration is based on releasing growth factors from alpha granules in platelets, which can induce osteogenesis. Moreover, the presence of fibrin nano-fiber structures as a constituent can provide a good substrate for cell attachments. This study attempts to review the history, structure, and biology of platelet-rich fibrin (PRF) as well as in vitro, pre-clinical, and clinical studies on the use of PRF for bone regeneration.

6 May 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
FHFatemeh Hosseini
Fatemeh Hosseini
MCMasoumeh Mirzaei Chegeni
Masoumeh Mirzaei Chegeni
ABAli Bidaki
Ali Bidaki
MZMohammad Zaer
Mohammad Zaer
HAHossein Abolhassani
Hossein Abolhassani
Mohammad Tavakkoli YarakiMohammad Tavakkoli Yaraki
Mohammad Tavakkoli Yaraki

24 September 2022 in Journal of Functional Biomaterials
Verified
Journal Article
Open access
PDF file
AFAhmad Reza Farmani
Ahmad Reza Farmani
MSMohammad Ali Salmeh
Mohammad Ali Salmeh
ZGZahra Golkar
Zahra Golkar
Alaa MoeinzadehAlaa Moeinzadeh
Alaa Moeinzadeh
FGFarzaneh Farid Ghiasi
Farzaneh Farid Ghiasi
Amir MostafaeiAmir Mostafaei
Amir Mostafaei
Lithium (Li) is a metal with critical therapeutic properties ranging from the treatment of bipolar depression to antibacterial, anticancer, antiviral and pro-regenerative effects. This element can be incorporated into the structure of various biomaterials through the inclusion of Li chloride/carbonate into polymeric matrices or being doped in bioceramics. The biocompatibility and multifunctionality of Li-doped bioceramics present many opportunities for biomedical researchers and clinicians. Li-doped bioceramics (capable of immunomodulation) have been used extensively for bone and tooth regeneration, and they have great potential for cartilage/nerve regeneration, osteochondral repair, and wound healing. The synergistic effect of Li in combination with other anticancer drugs as well as the anticancer properties of Li underline the rationale that bioceramics doped with Li may be impactful in cancer treatments. The role of Li in autophagy may explain its impact in regenerative, antiviral, and anticancer research. The combination of Li-doped bioceramics with polymers can provide new biomaterials with suitable flexibility, especially as bio-ink used in 3D printing for clinical applications of tissue engineering. Such Li-doped biomaterials have significant clinical potential in the foreseeable future.

14 April 2021 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
FMForough Mahdavinezhad
Forough Mahdavinezhad
RGRoghaye Gharaei
Roghaye Gharaei
AFAhmad Reza Farmani
Ahmad Reza Farmani
FHFarideh Hashemi
Farideh Hashemi
MKMahsa Kouhestani
Mahsa Kouhestani
FAFardin Amidi
Fardin Amidi

4 May 2021 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
AFAhmad Reza Farmani
Ahmad Reza Farmani
FMForough Mahdavinezhad
Forough Mahdavinezhad
RMRohollah Moslemi
Rohollah Moslemi
ZMZeinab Mehrabi
Zeinab Mehrabi
ANAlireza Noori
Alireza Noori
NRNima Rezaei
Nima Rezaei
Coronavirus disease 2019 (COVID-19) is associated with irreversible effects on vital organs, especially the respiratory and cardiac systems. While the immune system plays a key role in the survival of patients to viral infections, in COVID-19, there is a hyperinflammatory immune response evoked by all the immune cells, such as neutrophils, monocytes, and includes release of various cytokines, resulting in an exaggerated immune response, named cytokine storm. This severe, dysregulated immune response causes multi-organ damage, which eventually leads to high mortality. One of the most important components of hypersensitivity is immunoglobulin E (IgE), which plays a major role in susceptibility to respiratory infections and can lead to the activation of mast cells. There is also a negative association between IgE and IFN-α, which can reduce Toll-like receptor (TLR) nine receptor expression and TLR-7 signaling to disrupt IFN production. Moreover, anti-IgE drugs such as omalizumab reduces the severity and duration of COVID-19. In addition to its anti-IgE effect, omalizumab inhibits inflammatory cells such as neutrophils. Hence, blockade of IgE may have clinical utility as an immunotherapy for COVID-19.